Distinguishing types 1 and 2M von Willebrand disease

Discrimination of types 1 and 2M von Willebrand disease (VWD) is problematic. Type 1 VWD represents a quantitative deficiency of von Willebrand factor and type 2M a qualitative disorder. 2M VWD is considered a potentially more serious bleeding disorder than type 1 VWD and may also require a differential management approach given the higher bleeding risk and that desmopressin may be less effective. We describe a case of 2M VWD ‘masquerading’ as type 1 and show how the differential diagnosis can be obtained using standard laboratory assays. The case was genetically confirmed as a 3943C>T mutation, leading to R1315C.

[1]  E. Favaloro,et al.  von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder , 2011, Seminars in thrombosis and hemostasis.

[2]  E. Favaloro,et al.  Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay , 2010, Journal of thrombosis and haemostasis : JTH.

[3]  E. Favaloro,et al.  Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[4]  E. Favaloro,et al.  Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? , 2009, Thrombosis research.

[5]  E. Favaloro Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD): a rebuttal , 2008, Journal of thrombosis and haemostasis : JTH.

[6]  E. Favaloro,et al.  Lower Limit of Assay Sensitivity: An Under-recognised and Significant Problem in von Willebrand Disease Identification and Classification , 2008, American Society for Clinical Laboratory Science.

[7]  J. Goudemand,et al.  Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) , 2008, Journal of thrombosis and haemostasis : JTH.

[8]  P. James,et al.  Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  L. O'Brien,et al.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. , 2007, Blood.

[10]  P. Mannucci,et al.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.

[11]  A. Street,et al.  Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program. , 2006, Seminars in thrombosis and hemostasis.

[12]  S. Kitchen,et al.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. , 2006, Seminars in thrombosis and hemostasis.

[13]  J. Goudemand,et al.  The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. , 2001, Blood.

[14]  F. Martínez,et al.  Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene: New mutations, R1315C and R1341W, associated with type 2M and 2B variants , 1998, American journal of hematology.